(RF) Eurazeo - Ratings and Ratios
Investments, RealEstate, ConsumerBrands, Healthcare, Technology
Description: RF Eurazeo
Eurazeo SE is a private equity and venture capital firm that specializes in various investment strategies, including growth capital, acquisitions, and leveraged buyouts, targeting private and public companies across different sectors and geographies.
The firms investment focus is on medium-sized to large companies, SMEs, and high-growth businesses, with a particular emphasis on sectors driven by digital transformation and changes in lifestyle and consumption, such as smart cities, fintech, luxury, and healthcare. Eurazeo also invests in real estate management and development projects, particularly in Western Europe.
From a performance perspective, Eurazeos Return on Equity (RoE) stands at 17.89%, indicating a relatively strong ability to generate profits from shareholder equity. With a market capitalization of approximately €4.5 billion, Eurazeo is a significant player in the European private equity and venture capital landscape.
In terms of investment size, Eurazeo typically invests between €50 million to €250 million in small to mid-buyout businesses, €25 million to €100 million in growth businesses, and €10 million to €40 million in other opportunities. The firms investment activities are diversified across various regions, including Europe, North America, and China.
To evaluate Eurazeos performance, key performance indicators (KPIs) such as Assets Under Management (AUM) growth, investment portfolio return, and dividend yield can be considered. Additionally, metrics like the firms internal rate of return (IRR) and cash-on-cash return can provide insights into its investment performance.
RF Stock Overview
| Market Cap in USD | 4,439m |
| Sub-Industry | Asset Management & Custody Banks |
| IPO / Inception |
RF Stock Ratings
| Growth Rating | -16.0% |
| Fundamental | 38.4% |
| Dividend Rating | 74.7% |
| Return 12m vs S&P 500 | -34.6% |
| Analyst Rating | - |
RF Dividends
| Dividend Yield 12m | 4.42% |
| Yield on Cost 5y | 6.51% |
| Annual Growth 5y | 12.70% |
| Payout Consistency | 92.7% |
| Payout Ratio | 8.6% |
RF Growth Ratios
| Growth Correlation 3m | -63.2% |
| Growth Correlation 12m | -73.8% |
| Growth Correlation 5y | 32.5% |
| CAGR 5y | 3.62% |
| CAGR/Max DD 3y | 0.10 |
| CAGR/Mean DD 3y | 0.39 |
| Sharpe Ratio 12m | 1.43 |
| Alpha | -37.67 |
| Beta | 0.678 |
| Volatility | 24.64% |
| Current Volume | 177.2k |
| Average Volume 20d | 167.8k |
| Stop Loss | 52.1 (-3.2%) |
| Signal | -0.83 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-711.6m TTM) > 0 and > 6% of Revenue (6% = 26.8m TTM) |
| FCFTA -0.00 (>2.0%) and ΔFCFTA 0.00pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -281.6% (prev -5.39%; Δ -276.2pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.00 (>3.0%) and CFO 25.9m > Net Income -711.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 0.28 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (70.4m) change vs 12m ago -2.82% (target <= -2.0% for YES) |
| Gross Margin -28.70% (prev 64.25%; Δ -92.95pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 4.85% (prev 82.25%; Δ -77.40pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -7.00 (EBITDA TTM -506.3m / Interest Expense TTM 77.5m) >= 6 (WARN >= 3) |
Altman Z'' 4.49
| (A) -0.14 = (Total Current Assets 484.3m - Total Current Liabilities 1.74b) / Total Assets 8.93b |
| (B) 0.72 = Retained Earnings (Balance) 6.41b / Total Assets 8.93b |
| (C) -0.06 = EBIT TTM -542.5m / Avg Total Assets 9.22b |
| (D) 3.30 = Book Value of Equity 6.74b / Total Liabilities 2.04b |
| Total Rating: 4.49 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 38.39
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -0.43% = -0.21 |
| 3. FCF Margin -5.02% = -1.88 |
| 4. Debt/Equity 0.25 = 2.47 |
| 5. Debt/Ebitda -3.28 = -2.50 |
| 6. ROIC - WACC data missing |
| 7. RoE -9.60% = -1.60 |
| 8. Rev. Trend -66.53% = -3.33 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend -62.02% = -1.55 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of RF shares?
Over the past week, the price has changed by -0.09%, over one month by -2.36%, over three months by -9.88% and over the past year by -22.23%.
Is Eurazeo a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RF is around 46.62 EUR . This means that RF is currently overvalued and has a potential downside of -13.35%.
Is RF a buy, sell or hold?
What are the forecasts/targets for the RF price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 77.7 | 44.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 52 | -3.4% |
RF Fundamental Data Overview
Market Cap EUR = 3.79b (3.79b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 201.7m EUR (Cash And Short Term Investments, last quarter)
P/S = 640.9638
P/B = 0.5596
Beta = 1.353
Revenue TTM = 446.9m EUR
EBIT TTM = -542.5m EUR
EBITDA TTM = -506.3m EUR
Long Term Debt = 300.1m EUR (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 1.36b EUR (from shortTermDebt, last quarter)
Debt = 1.66b EUR (Calculated: Short Term 1.36b + Long Term 300.1m)
Net Debt = 1.55b EUR (from netDebt column, last quarter)
Enterprise Value = 5.24b EUR (3.79b + Debt 1.66b - CCE 201.7m)
Interest Coverage Ratio = -7.00 (Ebit TTM -542.5m / Interest Expense TTM 77.5m)
FCF Yield = -0.43% (FCF TTM -22.5m / Enterprise Value 5.24b)
FCF Margin = -5.02% (FCF TTM -22.5m / Revenue TTM 446.9m)
Net Margin = -159.2% (Net Income TTM -711.6m / Revenue TTM 446.9m)
Gross Margin = -28.70% ((Revenue TTM 446.9m - Cost of Revenue TTM 575.1m) / Revenue TTM)
Tobins Q-Ratio = 0.78 (Enterprise Value 5.24b / Book Value Of Equity 6.74b)
Interest Expense / Debt = 4.67% (Interest Expense 77.5m / Debt 1.66b)
Taxrate = unknown
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 0.28 (Total Current Assets 484.3m / Total Current Liabilities 1.74b)
Debt / Equity = 0.25 (Debt 1.66b / last Quarter total Stockholder Equity 6.63b)
Debt / EBITDA = -3.28 (Net Debt 1.55b / EBITDA -506.3m)
Debt / FCF = -73.87 (Debt 1.66b / FCF TTM -22.5m)
Total Stockholder Equity = 7.42b (last 4 quarters mean)
RoA = -7.96% (Net Income -711.6m, Total Assets 8.93b )
RoE = -9.60% (Net Income TTM -711.6m / Total Stockholder Equity 7.42b)
RoCE = -7.03% (Ebit -542.5m / (Equity 7.42b + L.T.Debt 300.1m))
RoIC = unknown (NOPAT none, Invested Capital 8.81b, Ebit -542.5m)
WACC = unknown (E(3.79b)/V(5.44b) * Re(8.51%)) + (D(1.66b)/V(5.44b) * Rd(4.67%) * (1-Tc(none)))
Shares Correlation 3-Years: -27.27 | Cagr: -0.71%
Discount Rate = 8.51% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -22.5m)
EPS Correlation: -62.02 | EPS CAGR: 0.0% | SUE: 0.0 | # QB: False
Revenue Correlation: -66.53 | Revenue CAGR: 0.0%